Overview of Bispecifics for R/R Multiple Myeloma
Panelist discusses how the RRMM treatment landscape has evolved significantly, with BiTEs emerging as a promising approach. BCMA-targeted BiTEs showed efficacy, while GPRC5D-targeting agents like talquetamab represent promising new options, particularly for patients with BCMA-refractory disease. Key challenges include managing cytokine release syndrome, developing optimal sequencing strategies, addressing drug resistance, and improving accessibility and affordability of novel therapies.
Video content above is prompted by the following:
- How has the treatment landscape evolved in RRMM?
- Please elaborate on the role of bispecific T-cell engagers (BiTEs) as well as the development of BiTE targets beyond BCMAs, focusing on GPRC5D.
- What are the key unmet needs and challenges in managing patients with RRMM?
- What are the main barriers to effective treatment and optimal outcomes for this patient population?
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More
